Skip to main content
Back
HCM logo

HUTCHMED (China) Limited

Data quality: 100%
HCM
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$14.12
▲ $0.12 (0.86%)
Mkt Cap: 2.55B
Also listed as HMDCF OTC
Day Range
$13.84 $14.12
52-Week Range
$11.51 $19.50
Volume
16,136
50D / 200D Avg
$14.74 / $15.33
Prev Close
$14.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 5.6 0.4
P/B 2.1 2.9
ROE % 45.9 3.7
Net Margin % 83.3 3.9
Rev Growth 5Y % 11.5 10.0
D/E 0.1 0.2

Analyst Price Target

Hold
$17.50 +23.9%
Forward P/E
44.1
Forward EPS
$0.32
EPS Growth (est.)
+0.0%
Est. Revenue
640 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.17
$1.09 – $1.35
 1.2 B 1
FY2029 $0.88
$0.82 – $1.02
 1.1 B 1
FY2028 $0.60
$0.56 – $0.69
 840 M 1

Key Takeaways

Revenue grew 11.48% annually over 5 years — strong growth
Earnings grew 1114.23% over the past year
ROE of 45.86% indicates high profitability
Net margin of 83.30% shows strong profitability
Debt/Equity of 0.08 — conservative balance sheet
Negative free cash flow of -79.01M

Growth

Revenue Growth (5Y)
11.48%
Revenue (1Y)-12.73%
Earnings (1Y)1114.23%
FCF Growth (3Y)N/A

Quality

Return on Equity
45.86%
ROIC-3.07%
Net Margin83.30%
Op. Margin-9.95%

Safety

Debt / Equity
0.08
Current Ratio4.96
Interest Coverage-19.05

Valuation

P/E Ratio
5.57
P/B Ratio2.06
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -12.73% Revenue Growth (3Y) -18.99%
Earnings Growth (1Y) 1114.23% Earnings Growth (3Y) 113.21%
Revenue Growth (5Y) 11.48% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 549.96M Net Income (TTM) 458.12M
ROE 45.86% ROA 26.13%
Gross Margin 38.68% Operating Margin -9.95%
Net Margin 83.30% Free Cash Flow (TTM) -79.01M
ROIC -3.07% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.08 Current Ratio 4.96
Interest Coverage -19.05 Dividend Yield 0.00%
Valuation
P/E Ratio 5.57 P/B Ratio 2.06
P/S Ratio 4.64 PEG Ratio 0.00
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.55B Enterprise Value 2.58B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 549.96M 630.20M 838.00M 426.41M 356.13M
Net Income 458.12M 37.73M 100.78M -360.84M -194.65M
EPS (Diluted) 2.60 0.22 0.60 -2.15 -1.25
Gross Profit 212.72M 281.32M 453.55M 115.31M 97.89M
Operating Income -54.73M -43.71M 18.38M -409.77M -344.29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.75B 1.27B 1.28B 1.03B 1.37B
Total Liabilities 501.84M 502.34M 536.39M 392.58M 333.15M
Shareholders' Equity 1.24B 759.93M 730.54M 610.37M 986.89M
Total Debt 97.89M 89.82M 86.13M 27.01M 38.98M
Cash & Equivalents 71.33M 153.96M 283.59M 313.28M 377.54M
Current Assets 1.57B 1.07B 1.10B 839.89M 1.21B
Current Liabilities 315.78M 376.56M 403.03M 353.90M 311.66M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#20 of 670
85

Recent Activity

Entered Contrarian Investing (David Dreman)
Mar 24, 2026